Combined Gene Therapy of Cancer Directed at Tumor Stem Cells and Patients Hematopoietic Stem Cells
Michael Lerman*
Cancer-Causing Genes Section, Laboratory of Immunobiology, National Cancer Institute, Frederick, Maryland, United States of America
*Corresponding author: Lerman M, Cancer-Causing Genes Section, Laboratory of Immunobiology, National Cancer Institute, Frederick, Maryland, USA, Email: lermanmi@gmail.com
Received Date: 18 November, 2016; Accepted Date: 5 December, 2016; Published Date: 12 December, 2016
Citation: Lerman M (2016) Combined Gene Therapy of Cancer Directed at Tumor Stem Cells and Patients Hematopoietic Stem Cells. J Oncol Res Ther 2016: J108. DOI: 10.29011/2574-710X.000008
The essence of my proposal is to use two known tumor suppressor genes expressed from episomal vectors: one delivered to cancer stem cells to suppress tumor growth, the other delivered to patient’s hematopoietic stem cells to boost the immune system to attack and destroy the tumor.
This cure program applies to all forms of cancer and all patients regardless of their genetic background, gender and age. It totally departs from the prevailing dogma that requires specific therapeutics with “targeted” drugs for each type of cancer, to be tailored to each individual tumor and patient background (“personalized treatment”).
© by the Authors & Gavin Publishers. This is an Open Access Journal Article Published Under Attribution-Share Alike CC BY-SA: Creative Commons Attribution-Share Alike 4.0 International License. Read More About Open Access Policy.